Mabwell (688062.SH), a China-based biopharmaceutical company, on Friday announced, the 'Preclinical Development of 7MW4811, an Mtoxin (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumours' as a poster presentation at the 15th World ADC San Diego, which ran from from 4 November to 7 November 2024.

The company said that the post revealed compelling data from the studies on the efficacy of 7MW4811 in the treatment of solid tumours.

7MW4811 has been developed with Mabwell's next-generation ADC technology (IDDC) platform, and is claimed to have demonstrated encouraging anti-tumour impacts across a range of solid tumours, which includes lung, colorectal, pancreatic and gastric cancers. It is also claimed to have indicated particularly promising therapeutic potentials in gastrointestinal tumours.

According to the company, IDDC, a clinically validated, site-specific conjugation technology, has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin (MF6), these ADCs have been furthered optimised, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.